NPS Pharma's hypoparathyroidism treatment 'Natpara' wins FDA approval

January 24, 2015 1:08 AM

10 0

NPS Pharmaceuticals' Natpara has received approval from the US FDA for treatment of rare hormonal abnormality - hypoparathyroidism.

The approval vindicates the gamble taken by Shire Plc to buy the company for $5.2 billion.

Also read: FDA OKs 2nd gene therapy for blood cancer; 1st for adults

Read more

To category page